New Blood Test Could Detect Alzheimer’s Years Early
新型血液檢測有望提前數年診斷出阿茲海默症
A groundbreaking shift is occurring in medical diagnostics, moving us from reactive treatment to proactive health management.
醫學診斷正在發生開創性的轉變，將我們從被動治療推向主動的健康管理。
Scientists have identified a key protein, p-tau217, as a reliable biomarker for Alzheimer’s disease.
科學家已鑑定出一種關鍵蛋白質p-tau217，可作為阿茲海默症的可靠生物標誌。
Historically, diagnosing Alzheimer’s required invasive PET scans or spinal taps, which were often costly and inaccessible.
過去診斷阿茲海默症需要侵入性的PET掃描或脊髓穿刺，這些檢查往往昂貴且難以取得。
By identifying the disease early, researchers can better select candidates for clinical trials, and patients gain the opportunity for early intervention and better long-term care planning.
透過早期鑑定疾病，研究人員能更好地篩選臨床試驗的候選者，而患者也能獲得早期干預及更好的長期照護規劃的機會。
While these tests aren't yet a routine check-up tool for everyone, they represent a monumental leap forward in our ability to intercept Alzheimer’s.
儘管這些檢測尚未成為全民的常規健檢工具，但它們代表了我們攔截阿茲海默症能力上的重大飛躍。
